Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Stephen Michael Kelsey, President of Research and Development at Revolution Medicines (NASDAQ: RVMD), reported significant insider trading activity on June 16, 2025. The transaction involved the disposition of 4,289 shares at a weighted average price of $39.83 per share.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Kelsey maintains beneficial ownership of 289,414 shares, which includes:
- 94,426 Restricted Stock Units (RSUs)
- 652 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
The transaction prices ranged from $39.60 to $39.83, with the reporting person agreeing to provide detailed price-specific transaction information upon request to relevant parties.
Revolution Medicines (RVMD) Chief Medical Officer Wei Lin reported insider trading activity on June 16, 2025. The transaction involved the sale of 2,173 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.60 to $39.83.
The sale was conducted under a Rule 10b5-1 trading plan established on December 23, 2024, specifically to address tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Lin maintains beneficial ownership of 90,499 shares, which includes:
- 1,021 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
- 64,800 restricted stock units (RSUs)
This transaction represents a planned sale for tax purposes rather than a discretionary trading decision by the insider, as evidenced by the pre-established 10b5-1 plan.